
George A Bray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2368575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Changes in pedometerâ€measured physical activity are associated with weight loss and changes in body composition and fat distribution in response to reducedâ€energy diet interventions: The <scp>POUNDS Lost</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1000-1009.	2.2	3
2	Sleep Disturbance and Changes in Energy Intake and Body Composition During Weight Loss in the POUNDS Lost Trial. Diabetes, 2022, 71, 934-944.	0.3	3
3	Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care, 2022, 45, 1252-1259.	4.3	23
4	Evidenceâ€based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 50-62.	2.2	53
5	Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 929-936.	1.7	16
6	Genetically determined SCFA concentration modifies the association of dietary fiber intake with changes in bone mineral density during weight loss: The Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. American Journal of Clinical Nutrition, 2021, 114, 42-48.	2.2	6
7	Effect of 8Âweeks of supervised overfeeding on eating attitudes and behaviors, eating disorder symptoms, and body image: Results from the PROOF and EAT studies. Eating Behaviors, 2021, 43, 101570.	1.1	0
8	Therapeutic Management of Obesity. Contemporary Cardiology, 2021, , 323-339.	0.0	1
9	The Obesity Society is turning 40: A history of the early years. Obesity, 2021, 29, 1978-1981.	1.5	1
10	The pain of weight gain: self-experimentation with overfeeding. American Journal of Clinical Nutrition, 2020, 111, 17-20.	2.2	7
11	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
12	Predicting Weight Loss Using Psychological and Behavioral Factors: The POUNDS LOST Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1274-1283.	1.8	6
13	Genetic variation in lean body mass, changes of appetite and weight loss in response to diet interventions: The <scp>POUNDS</scp> Lost trial. Diabetes, Obesity and Metabolism, 2020, 22, 2305-2315.	2.2	11
14	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
15	Effect of Overeating Dietary Protein at Different Levels on Circulating Lipids and Liver Lipid: The PROOF Study. Nutrients, 2020, 12, 3801.	1.7	1
16	The biology of human overfeeding: A systematic review. Obesity Reviews, 2020, 21, e13040.	3.1	52
17	Changes of Branched-Chain Amino Acids and Ectopic Fat in Response to Weight-loss Diets: the POUNDS Lost Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3747-e3756.	1.8	7
18	In the Footsteps of Wilbur Olin Atwater: The Atwater Lecture for 2019. Advances in Nutrition, 2020, 11, 743-750.	2.9	2

#	Article	IF	CITATIONS
19	Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial. Gut, 2019, 68, 263-270.	6.1	123
20	Perfluoroalkyl substances and changes in bone mineral density: A prospective analysis in the POUNDS-LOST study. Environmental Research, 2019, 179, 108775.	3.7	25
21	Genetic Susceptibility, Dietary Protein Intake, and Changes of Blood Pressure. Hypertension, 2019, 74, 1460-1467.	1.3	12
22	Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial. Diabetes Care, 2019, 42, 1365-1371.	4.3	31
23	Lessons Learned from the POUNDS Lost Study: Genetic, Metabolic, and Behavioral Factors Affecting Changes in Body Weight, Body Composition, and Cardiometabolic Risk. Current Obesity Reports, 2019, 8, 262-283.	3.5	26
24	Is There an Ideal Diet?. Obesity, 2019, 27, 690-690.	1.5	1
25	Pretreatment Fasting Glucose and Insulin as Determinants of Weight Loss on Diets Varying in Macronutrients and Dietary Fibers—The POUNDS LOST Study. Nutrients, 2019, 11, 586.	1.7	26
26	GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans. Cell Metabolism, 2019, 29, 707-718.e8.	7.2	286
27	Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions. Diabetologia, 2019, 62, 58-69.	2.9	25
28	A circadian rhythm-related MTNR1B genetic variant modulates the effect of weight-loss diets on changes in adiposity and body composition: the POUNDS Lost trial. European Journal of Nutrition, 2019, 58, 1381-1389.	1.8	27
29	Plasma fatty acyl-carnitines during 8†weeks of overfeeding: relation to diet energy expenditure and body composition: the PROOF study. Metabolism: Clinical and Experimental, 2018, 83, 1-10.	1.5	6
30	Gut-microbiome-related LCT genotype and 2-year changes in body composition and fat distribution: the POUNDS Lost Trial. International Journal of Obesity, 2018, 42, 1565-1573.	1.6	16
31	<i>HNF1A</i> variant, energyâ€reduced diets and insulin resistance improvement during weight loss: The POUNDS Lost trial and DIRECT. Diabetes, Obesity and Metabolism, 2018, 20, 1445-1452.	2.2	17
32	Macronutrient-specific effect of the MTNR1B genotype on lipid levels in response to 2 year weight-loss diets. Journal of Lipid Research, 2018, 59, 155-161.	2.0	20
33	Plasma Amino Acids During 8 Weeks of Overfeeding: Relation to Diet Body Composition and Fat Cell Size in the PROOF Study. Obesity, 2018, 26, 324-331.	1.5	7
34	Changes in Gut Microbiota–Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial. Diabetes Care, 2018, 41, 413-419.	4.3	61
35	Genetic, epigenetic and transcriptional variations at NFATC2IP locus with weight loss in response to diet interventions: The POUNDS Lost Trial. Diabetes, Obesity and Metabolism, 2018, 20, 2298-2303.	2.2	27
36	The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocrine Reviews, 2018, 39, 79-132.	8.9	522

#	Article	IF	CITATIONS
37	Genetically determined vitamin D levels and change in bone density during a weight-loss diet intervention: the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) Trial. American Journal of Clinical Nutrition, 2018, 108, 1129-1134.	2.2	9
38	90th Anniversary Commentary: Consumption of Sweetened Beverages Predicts the Occurrence of Type 2 Diabetes. Journal of Nutrition, 2018, 148, 1688-1690.	1.3	0
39	The War Diet Squad. Obesity, 2018, 26, 1389-1389.	1.5	0
40	Perfluoroalkyl substances and changes in body weight and resting metabolic rate in response to weight-loss diets: A prospective study. PLoS Medicine, 2018, 15, e1002502.	3.9	117
41	Genetic variations of circulating adiponectin levels modulate changes in appetite in response to weight-loss diets. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2909.	1.8	11
42	Dietary Protein Modifies the Effect of the MC4R Genotype on 2-Year Changes in Appetite and Food Craving: The POUNDS Lost Trial. Journal of Nutrition, 2017, 147, jn242958.	1.3	17
43	Diet and Blood Pressure: The High and Low of it. , 2017, , 123-128.		0
44	Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology, 2017, 88, 2026-2035.	1.5	59
45	Obesity. Nature Reviews Disease Primers, 2017, 3, 17034.	18.1	766
46	Frequency of Consuming Foods Predicts Changes in Cravings for Those Foods During Weight Loss: The POUNDS Lost Study. Obesity, 2017, 25, 1343-1348.	1.5	14
47	A Systems Genetics Approach Identified GPD1L and its Molecular Mechanism for Obesity in Human Adipose Tissue. Scientific Reports, 2017, 7, 1799.	1.6	14
48	Markers of dietary protein intake are associated with successful weight loss in the <scp>POUNDS</scp> Lost trial. Clinical Obesity, 2017, 7, 166-175.	1.1	25
49	Obesity and the Risk for Type 2 Diabetes. , 2017, , 677-689.		0
50	The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. Journal of Bone and Mineral Research, 2017, 32, 2278-2287.	3.1	57
51	Establishing energy requirements for body weight maintenance: validation of an intake-balance method. BMC Research Notes, 2017, 10, 220.	0.6	10
52	Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3381-3389.	1.8	32
53	Starch Digestion–Related Amylase Genetic Variant Affects 2-Year Changes in Adiposity in Response to Weight-Loss Diets: The POUNDS Lost Trial. Diabetes, 2017, 66, 2416-2423.	0.3	29
54	Obesity: Understanding and Achieving a Healthy Weight. , 2017, , 73-90.		0

#	Article	IF	CITATIONS
55	Greater Healthful Dietary Variety Is Associated with Greater 2-Year Changes in Weight and Adiposity in the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) Trial. Journal of Nutrition, 2016, 146, 1552-1559.	1.3	22
56	Effect of Three Levels of Dietary Protein on Metabolic Phenotype of Healthy Individuals With 8 Weeks of Overfeeding. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2836-2843.	1.8	12
57	The Role of Macronutrient Content in the Diet for Weight Management. Endocrinology and Metabolism Clinics of North America, 2016, 45, 581-604.	1.2	32
58	Changes in regional body composition over 8 years in a randomized lifestyle trial: The look AHEAD study. Obesity, 2016, 24, 1899-1905.	1.5	8
59	Plasma Taurine, Diabetes Genetic Predisposition, and Changes of Insulin Sensitivity in Response to Weight-Loss Diets. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3820-3826.	1.8	26
60	Weighing up dietary patterns – Authors' reply. Lancet, The, 2016, 388, 759-760.	6.3	3
61	Macronutrient Intake–Associated <i>FGF21</i> Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial. Diabetes Care, 2016, 39, 1909-1914.	4.3	50
62	Weight management and exercise: any advantage?. American Journal of Clinical Nutrition, 2016, 104, 547-548.	2.2	1
63	No evidence for metabolic adaptation in thermic effect of food by dietary protein. Obesity, 2016, 24, 1639-1642.	1.5	11
64	Genetic susceptibility to diabetes and long-term improvement of insulin resistance and β cell function during weight loss: the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. American Journal of Clinical Nutrition, 2016, 104, 198-204.	2.2	30
65	Is Sugar Addictive?. Diabetes, 2016, 65, 1797-1799.	0.3	6
66	Weight-Loss Diets, Adiponectin, and Changes in Cardiometabolic Risk in the 2-Year POUNDS Lost Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2415-2422.	1.8	42
67	Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trials. American Journal of Clinical Nutrition, 2016, 103, 505-511.	2.2	69
68	New compartment model analysis of lean-mass and fat-mass growth with overfeeding. Nutrition, 2016, 32, 590-600.	1.1	0
69	Management of obesity. Lancet, The, 2016, 387, 1947-1956.	6.3	715
70	Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. American Journal of Clinical Nutrition, 2016, 103, 341-347.	2.2	240
71	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice, 2015, 21, 1-87.	1.1	443
72	Ankleâ€brachial index and interâ€artery blood pressure differences as predictors of cognitive function in overweight and obese older adults with diabetes: results from the Action for Health in Diabetes movement and memory study. International Journal of Geriatric Psychiatry, 2015, 30, 999-1007.	1.3	5

#	Article	IF	CITATIONS
73	CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials. Journal of Lipid Research, 2015, 56, 713-721.	2.0	39
74	From farm to fat cell: why aren't we all fat?. Metabolism: Clinical and Experimental, 2015, 64, 349-353.	1.5	13
75	Effect of protein overfeeding on energy expenditure measured in a metabolic chamber. American Journal of Clinical Nutrition, 2015, 101, 496-505.	2.2	50
76	Improving longâ€ŧerm weight loss maintenance: Can we do it?. Obesity, 2015, 23, 2-3.	1.5	30
77	Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. Obesity, 2015, 23, 565-572.	1.5	55
78	Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study). American Journal of Clinical Nutrition, 2015, 101, 449-454.	2.2	35
79	<i>PCSK7</i> Genotype Modifies Effect of a Weight-Loss Diet on 2-Year Changes of Insulin Resistance: The POUNDS LOST Trial. Diabetes Care, 2015, 38, 439-444.	4.3	35
80	Why Obesity?. Annual Review of Nutrition, 2015, 35, 1-31.	4.3	7
81	Sex Differences in the Effects of Weight Loss Diets on Bone Mineral Density and Body Composition: POUNDS LOST Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2463-2471.	1.8	44
82	Dietary Fat Modifies the Effects of FTO Genotype on Changes in Insulin Sensitivity. Journal of Nutrition, 2015, 145, 977-982.	1.3	30
83	Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial. Journal of Nutrition, 2015, 145, 1289-1294.	1.3	33
84	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. Circulation, 2015, 132, 691-718.	1.6	303
85	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. Diabetes Care, 2015, 38, 1567-1582.	4.3	180
86	Vitamin D metabolism-related genetic variants, dietary protein intake and improvement of insulin resistance in a 2Âyear weight-loss trial: POUNDS Lost. Diabetologia, 2015, 58, 2791-2799.	2.9	20
87	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	4.3	346
88	Neuropeptide Y genotype, central obesity, and abdominal fat distribution: the POUNDS LOST trial. American Journal of Clinical Nutrition, 2015, 102, 514-519.	2.2	36
89	Diabetes and Obesity—Time Bombs to Be Defused. Diabetes Care, 2015, 38, 1997-1999.	4.3	10
90	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes, 2015, 64, 989-998.	0.3	43

#	Article	IF	CITATIONS
91	Aging and Physical Function in Type 2 Diabetes: 8 Years of an Intensive Lifestyle Intervention. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 345-353.	1.7	43
92	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. Growth Hormone, 2015, , 91-109.	0.2	0
93	American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action. Endocrine Practice, 2014, 20, 956-976.	1.1	33
94	Update on obesity pharmacotherapy. Annals of the New York Academy of Sciences, 2014, 1311, 1-13.	1.8	74
95	An objective estimate of energy intake during weight gain using the intake-balance method , ,. American Journal of Clinical Nutrition, 2014, 100, 806-812.	2.2	26
96	Effects of weight gain induced by controlled overfeeding on physical activity. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E1030-E1037.	1.8	26
97	Short-term overeating results in incomplete energy intake compensation regardless of energy density or macronutrient composition. Obesity, 2014, 22, 119-130.	1.5	16
98	Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?. Diabetes Care, 2014, 37, 950-956.	4.3	329
99	Overfeeding of Polyunsaturated Versus Saturated Fatty Acids Reduces Ectopic Fat. Diabetes, 2014, 63, 2222-2224.	0.3	6
100	FTO genotype, dietary protein, and change in appetite: the Preventing Overweight Using Novel Dietary Strategies trial. American Journal of Clinical Nutrition, 2014, 99, 1126-1130.	2.2	63
101	Medical treatment of obesity: The past, the present and the future. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 665-684.	1.0	70
102	JCL Roundtable: Clinical management of individuals with obesity. Journal of Clinical Lipidology, 2014, 8, 237-248.	0.6	0
103	Variants in glucose- and circadian rhythm–related genes affect the response of energy expenditure to weight-loss diets: the POUNDS LOST Trial. American Journal of Clinical Nutrition, 2014, 99, 392-399.	2.2	47
104	FGF21 is an endocrine signal of protein restriction. Journal of Clinical Investigation, 2014, 124, 3913-3922.	3.9	451
105	Pharmacologic Treatment Options for Obesity: What Is Old Is New Again. Current Hypertension Reports, 2013, 15, 182-189.	1.5	34
106	Day-to-Day Variation in Food Intake and Energy Expenditure in Healthy Women: The Dietitian II Study. Journal of the Academy of Nutrition and Dietetics, 2013, 113, 1532-1538.	0.4	35
107	Potential Health Risks From Beverages Containing Fructose Found in Sugar or High-Fructose Corn Syrup. Diabetes Care, 2013, 36, 11-12.	4.3	1,192
108	Why do we need drugs to treat the patient with obesity?. Obesity, 2013, 21, 893-899.	1.5	33

#	Article	IF	CITATIONS
109	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
110	CD36 mRNA in the Gastrointestinal Tract Is Differentially Regulated by Dietary Fat Intake in Obesity-Prone and Obesity-Resistant Rats. Digestive Diseases and Sciences, 2013, 58, 363-370.	1.1	25
111	Treatment of the Obese Patient in Primary Care: Targeting and Meeting Goals and Expectations. Postgraduate Medicine, 2013, 125, 67-77.	0.9	24
112	<i>IRS1</i> Genotype Modulates Metabolic Syndrome Reversion in Response to 2-Year Weight-Loss Diet Intervention. Diabetes Care, 2013, 36, 3442-3447.	4.3	27
113	Genetic Determinant for Amino Acid Metabolites and Changes in Body Weight and Insulin Resistance in Response to Weight-Loss Diets. Circulation, 2013, 127, 1283-1289.	1.6	67
114	Energy and Fructose From Beverages Sweetened With Sugar or High-Fructose Corn Syrup Pose a Health Risk for Some People. Advances in Nutrition, 2013, 4, 220-225.	2.9	154
115	Dietary management of the metabolic syndrome – one size fits all?. Proceedings of the Nutrition Society, 2013, 72, 310-316.	0.4	4
116	<i>FTO</i> Genotype and 2-Year Change in Body Composition and Fat Distribution in Response to Weight-Loss Diets. Diabetes, 2012, 61, 3005-3011.	0.3	139
117	Effect of diet composition on energy expenditure during weight loss: the POUNDS LOST Study. International Journal of Obesity, 2012, 36, 448-455.	1.6	40
118	Use of a Computerized Tracking System to Monitor and Provide Feedback on Dietary Goals for Calorie-Restricted Diets: The POUNDS LOST Study. Journal of Diabetes Science and Technology, 2012, 6, 1216-1225.	1.3	39
119	Medical Therapy for the Patient With Obesity. Circulation, 2012, 125, 1695-1703.	1.6	98
120	Effect of Dietary Protein Content on Weight Gain, Energy Expenditure, and Body Composition During Overeating. JAMA - Journal of the American Medical Association, 2012, 307, 47.	3.8	221
121	Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial. American Journal of Clinical Nutrition, 2012, 95, 506-513.	2.2	77
122	APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost Trial. American Journal of Clinical Nutrition, 2012, 96, 917-922.	2.2	51
123	Fructose and Risk of Cardiometabolic Disease. Current Atherosclerosis Reports, 2012, 14, 570-578.	2.0	73
124	Zonisamide for Weight Reduction in Obese Adults. Archives of Internal Medicine, 2012, 172, 1557.	4.3	68
125	Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes. New England Journal of Medicine, 2012, 366, 1209-1217.	13.9	257
126	Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. American Journal of Clinical Nutrition, 2012, 95, 614-625.	2.2	161

#	Article	IF	CITATIONS
127	Effect of Diet Composition and Weight Loss on Resting Energy Expenditure in the POUNDS LOST Study. Obesity, 2012, 20, 2384-2389.	1.5	48
128	Patterns of Weight Change Associated With Longâ€Term Weight Change and Cardiovascular Disease Risk Factors in the Look AHEAD Study. Obesity, 2012, 20, 2048-2056.	1.5	71
129	Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial. Journal of Bone and Mineral Research, 2012, 27, 619-627.	3.1	68
130	Drug Treatment of Obesity. Psychiatric Clinics of North America, 2011, 34, 871-880.	0.7	13
131	Medications for Weight Reduction. Medical Clinics of North America, 2011, 95, 989-1008.	1.1	8
132	Body Image Changes Associated With Participation in an Intensive Lifestyle Weight Loss Intervention. Obesity, 2011, 19, 1290-1295.	1.5	17
133	Is dietary fat important?. American Journal of Clinical Nutrition, 2011, 93, 481-482.	2.2	7
134	Insulin Receptor Substrate 1 Gene Variation Modifies Insulin Resistance Response to Weight-Loss Diets in a 2-Year Randomized Trial. Circulation, 2011, 124, 563-571.	1.6	122
135	Impact of adopting a vegan diet or an olestra supplementation on plasma organochlorine concentrations: results from two pilot studies. British Journal of Nutrition, 2010, 103, 1433-1441.	1.2	25
136	Soft drink consumption and obesity: it is all about fructose. Current Opinion in Lipidology, 2010, 21, 51-57.	1.2	97
137	Medical Therapy for Obesity. Mount Sinai Journal of Medicine, 2010, 77, 407-417.	1.9	19
138	Combination Drugs for Treating Obesity. Current Diabetes Reports, 2010, 10, 108-115.	1.7	27
139	Adherence is a multi-dimensional construct in the POUNDS LOST trial. Journal of Behavioral Medicine, 2010, 33, 35-46.	1.1	49
140	Early behavioral adherence predicts short and long-term weight loss in the POUNDS LOST study. Journal of Behavioral Medicine, 2010, 33, 305-314.	1.1	50
141	There's More Than One Way to Skin A Cat: Response to "Reporting Weight Loss: Is Simple Better?― Obesity, 2010, 18, 651-651.	1.5	2
142	Response to "The Way We Report Weight Loss― Obesity, 2010, 18, 652-652.	1.5	0
143	Maintenance of weight loss: setting our goals higher. Nature Reviews Endocrinology, 2010, 6, 657-658.	4.3	4
144	Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings. Archives of Internal Medicine, 2010, 170, 146.	4.3	127

#	Article	IF	CITATIONS
145	Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes. Diabetes Care, 2010, 33, 2477-2483.	4.3	1,648
146	Sugar-Sweetened Beverages, Obesity, Type 2 Diabetes Mellitus, and Cardiovascular Disease Risk. Circulation, 2010, 121, 1356-1364.	1.6	1,315
147	Fructose: Pure, White, and Deadly? Fructose, by Any other Name, is a Health Hazard. Journal of Diabetes Science and Technology, 2010, 4, 1003-1007.	1.3	73
148	Adipose Tissue Collagen VI in Obesity. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5155-5162.	1.8	268
149	Is it Time to Change the Way We Report and Discuss Weight Loss?. Obesity, 2009, 17, 619-621.	1.5	50
150	Obesity: a failure of homeostasis because of hedonic rewards: response to the letter from Gary Taubes. Obesity Reviews, 2009, 10, 99-102.	3.1	1
151	Describing Patterns of Weight Changes Using Principal Components Analysis: Results from the Action for Health in Diabetes (Look AHEAD) Research Group. Annals of Epidemiology, 2009, 19, 701-710.	0.9	40
152	Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates. New England Journal of Medicine, 2009, 360, 859-873.	13.9	1,680
153	Medications for Obesity: Mechanisms and Applications. Clinics in Chest Medicine, 2009, 30, 525-538.	0.8	23
154	Gastrointestinal hormones and weight management. Lancet, The, 2009, 374, 1570-1571.	6.3	9
155	Tratamiento farmacológico de la obesidad. , 2009, , 73-82.		0
156	Are Nonâ€prescription Medications Needed for Weight Control?. Obesity, 2008, 16, 509-514.	1.5	22
157	Obesity as a Disease: A White Paper on Evidence and Arguments Commissioned by the Council of The Obesity Society. Obesity, 2008, 16, 1161-1177.	1.5	233
158	Medications for Weight Reduction. Endocrinology and Metabolism Clinics of North America, 2008, 37, 923-942.	1.2	21
159	Is new hope on the horizon for obesity?. Lancet, The, 2008, 372, 1859-1860.	6.3	7
160	The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 382-393.	2.9	216
161	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Review of Cardiovascular Therapy, 2008, 6, 343-368.	0.6	423
162	Corrective responses in human food intake identified from an analysis of 7-d food-intake records. American Journal of Clinical Nutrition, 2008, 88, 1504-1510.	2.2	55

#	Article	IF	CITATIONS
163	Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2008, 93, s81-s88.	1.8	97
164	Reply to RJ Hine and JS White. American Journal of Clinical Nutrition, 2008, 87, 1064-1065.	2.2	0
165	Treatment of Hypothalamic Obesity with Caffeine and Ephedrine. Endocrine Practice, 2008, 14, 697-703.	1.1	45
166	Treatment of the Metabolic Syndrome with Weight Loss, Exercise, Hormones, and Surgery. , 2008, , 57-73.		0
167	Fructosehow worried should we be?. Medscape Journal of Medicine, 2008, 10, 159.	0.6	5
168	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. Diabetes Care, 2007, 30, 1374-1383.	4.3	1,369
169	Epidemics of Obesity and Metabolic Disorders: Are Dietary Fats or Sugars Involved?. Current Nutrition and Food Science, 2007, 3, 113-121.	0.3	2
170	Pharmacological Treatment of the Overweight Patient. Pharmacological Reviews, 2007, 59, 151-184.	7.1	147
171	Body Size and Shape Changes and the Risk of Diabetes in the Diabetes Prevention Program. Diabetes, 2007, 56, 1680-1685.	0.3	104
172	How bad is fructose?1,2. American Journal of Clinical Nutrition, 2007, 86, 895-896.	2.2	113
173	Medical Therapy for Obesity—Current Status and Future Hopes. Medical Clinics of North America, 2007, 91, 1225-1253.	1.1	18
174	Hormonal Responses to a Fast-Food Meal Compared with Nutritionally Comparable Meals of Different Composition. Annals of Nutrition and Metabolism, 2007, 51, 163-171.	1.0	17
175	Drug Treatment of the Overweight Patient. Gastroenterology, 2007, 132, 2239-2252.	0.6	107
176	Drug Management in Obesity. , 2007, , 73-82.		2
177	Effect of Metaâ€chlorophenylpiperazine and Cholecystokinin on Food Intake of Osborneâ€Mendel and S5B/P1 Rats. Obesity, 2007, 15, 624-631.	1.5	12
178	Effect of NPY5R Antagonist MK-0557 on Weight Regain after Very-low-calorie Diet-induced Weight Loss*. Obesity, 2007, 15, 895-905.	1.5	51
179	Weight-Loss Drugs. , 2007, , 341-368.		2
180	Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss. Circulation, 2006, 113, 898-918.	1.6	2,378

#	Article	IF	CITATIONS
181	Obesity:Â The Disease. Journal of Medicinal Chemistry, 2006, 49, 4001-4007.	2.9	95
182	Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabolism, 2006, 4, 275-282.	7.2	174
183	Energy expenditure and substrate oxidation predict changes in body fat in children. American Journal of Clinical Nutrition, 2006, 84, 862-870.	2.2	39
184	Epidemiology, Trends, and Morbidities of Obesity and the Metabolic Syndrome. Endocrine, 2006, 29, 109-118.	2.2	356
185	Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in) Tj ETQq1 1 0.7843	014 rgBT /0	Dverlock 10 T
186	Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes. Diabetes Care, 2006, 29, 2102-2107.	4.3	1,050
187	Evaluation of the Overweight and Obese Patient. , 2006, , 169-186.		0
188	A Status of Drugs on the Horizon for Obesity and the Metabolic Syndrome—a Comprehensive Review 2005. , 2006, , 281-306.		0
189	Medical Approaches to Treatment of the Obese Patient. , 2006, , 457-469.		2
190	Beyond Energy Balance: There Is More to Obesity than Kilocalories. Journal of the American Dietetic Association, 2005, 105, 17-23.	1.3	94
191	Daily Intake of Multivitamins during Long-Term Intake of Olestra in Men Prevents Declines in Serum Vitamins A and E but Not Carotenoids. Journal of Nutrition, 2005, 135, 1456-1461.	1.3	11
192	Is There Something Special about Low-Carbohydrate Diets?. Annals of Internal Medicine, 2005, 142, 469.	2.0	3
193	Pharmacological Management of Obesity. , 2005, 171, 81-101.		0
194	Effect of a high or low ambient perinatal temperature on adult obesity in Osborne-Mendel and S5B/Pl rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 288, R1376-R1384.	0.9	16
195	Drug Insight: appetite suppressants. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 89-95.	1.7	24
196	Drug Treatment of Obesity. Psychiatric Clinics of North America, 2005, 28, 193-217.	0.7	8
197	A High-Fat Diet Coordinately Downregulates Genes Required for Mitochondrial Oxidative Phosphorylation in Skeletal Muscle. Diabetes, 2005, 54, 1926-1933.	0.3	534
198	Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism: Clinical and Experimental, 2005, 54, 24-32.	1.5	148

#	Article	IF	CITATIONS
199	Epidemiology, risks and pathogenesis of obesity. Meat Science, 2005, 71, 2-7.	2.7	7
200	Comparison of the acute response to meals enriched with cis- or trans-fatty acids on glucose and lipids in overweight individuals with differing FABP2 genotypes. Metabolism: Clinical and Experimental, 2005, 54, 1652-1658.	1.5	74
201	Reply to J Bigaard et al. American Journal of Clinical Nutrition, 2004, 80, 792.	2.2	0
202	Reply to MF Jacobson. American Journal of Clinical Nutrition, 2004, 80, 1081-1082.	2.2	18
203	Reply to NJ Krilanovich. American Journal of Clinical Nutrition, 2004, 80, 1447-1448.	2.2	1
204	Energy expenditure in African American and white boys and girls in a 2-y follow-up of the Baton Rouge Children's Study. American Journal of Clinical Nutrition, 2004, 79, 268-273.	2.2	54
205	Don't throw the baby out with the bath water. American Journal of Clinical Nutrition, 2004, 79, 347-349.	2.2	32
206	Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease. Circulation, 2004, 110, 2952-2967.	1.6	797
207	Effects of Diet and Time of the Day on Serum and CSF Leptin Levels in Osborneâ€Mendel and S5B/Pl Rats. Obesity, 2004, 12, 1067-1076.	4.0	20
208	Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. Obesity, 2004, 12, 1426-1434.	4.0	470
209	Obesity and the metabolic syndrome: implications for dietetics practitioners. Journal of the American Dietetic Association, 2004, 104, 86-89.	1.3	45
210	A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. American Journal of Cardiology, 2004, 94, 222-227.	0.7	207
211	Medical Consequences of Obesity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2583-2589.	1.8	1,251
212	How do we get fat? An epidemiologic and metabolic approach. Clinics in Dermatology, 2004, 22, 281-288.	0.8	15
213	The epidemic of obesity and changes in food intake: the Fluoride Hypothesis. Physiology and Behavior, 2004, 82, 115-121.	1.0	67
214	Effect of a β-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity. Physiology and Behavior, 2004, 82, 489-496.	1.0	21
215	Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiology and Behavior, 2004, 83, 549-555.	1.0	297
216	Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition, 2004, 79, 537-543.	2.2	1,567

#	Article	IF	CITATIONS
217	Obesity, Treatment of. , 2004, , 414-418.		Ο
218	Obesity, Treatment of. , 2004, , 1-5.		0
219	Noradrenergic, Serotonergic, Antiepileptic, and Herbal Drugs. , 2004, , 267-284.		1
220	Fast-food consumption among US adults and children: Dietary and nutrient intake profile. Journal of the American Dietetic Association, 2003, 103, 1332-1338.	1.3	560
221	A 6-Month Randomized, Placebo-Controlled, Dose-Ranging Trial of Topiramate for Weight Loss in Obesity. Obesity, 2003, 11, 722-733.	4.0	306
222	Risks of obesity. Primary Care - Clinics in Office Practice, 2003, 30, 281-299.	0.7	29
223	Risks of obesity. Endocrinology and Metabolism Clinics of North America, 2003, 32, 787-804.	1.2	130
224	Low-Carbohydrate Diets and Realities of Weight Loss. JAMA - Journal of the American Medical Association, 2003, 289, 1853.	3.8	55
225	Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults. JAMA - Journal of the American Medical Association, 2003, 289, 1826.	3.8	183
226	Evaluation of obesity. Postgraduate Medicine, 2003, 114, 19-38.	0.9	29
227	Estimation of energy requirements in a controlled feeding trial. American Journal of Clinical Nutrition, 2003, 77, 639-645.	2.2	47
228	Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes: A 1-year randomized controlled trial. Diabetes Care, 2002, 25, 1033-1041.	4.3	289
229	The Influence of Different Fats and Fatty Acids on Obesity, Insulin Resistance and Inflammation. Journal of Nutrition, 2002, 132, 2488-2491.	1.3	147
230	Prediction of body fat in 12-y-old African American and white children: evaluation of methods,,. American Journal of Clinical Nutrition, 2002, 76, 980-990.	2.2	101
231	The Underlying Basis for Obesity: Relationship to Cancer. Journal of Nutrition, 2002, 132, 3451S-3455S.	1.3	171
232	Effect on Body Weight of Replacing Dietary Fat with Olestra for Two or Ten Weeks in Healthy Men and Women. Journal of the American College of Nutrition, 2002, 21, 259-267.	1.1	22
233	Low-fat diets are preferred. American Journal of Medicine, 2002, 113, 41-46.	0.6	46
234	Effects of Diets Enriched in Saturated (Palmitic), Monounsaturated (Oleic), or trans (Elaidic) Fatty Acids on Insulin Sensitivity and Substrate Oxidation in Healthy Adults. Diabetes Care, 2002, 25, 1283-1288.	4.3	226

#	Article	IF	CITATIONS
235	A 9-mo randomized clinical trial comparing fat-substituted and fat-reduced diets in healthy obese men: the Ole Study,,. American Journal of Clinical Nutrition, 2002, 76, 928-934.	2.2	55
236	Predicting obesity in adults from childhood and adolescent weight. American Journal of Clinical Nutrition, 2002, 76, 497-498.	2.2	30
237	Americans on Diet. Journal of the American Dietetic Association, 2002, 102, 1247-1251.	1.3	39
238	Energy Intake and Energy Expenditure. Journal of the American Dietetic Association, 2002, 102, 1428-1432.	1.3	66
239	Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. New England Journal of Medicine, 2001, 344, 3-10.	13.9	4,625
240	Relationship of dietary fat and serum cholesterol ester and phospholipid fatty acids to markers of insulin resistance in men and women with a range of glucose tolerance. Metabolism: Clinical and Experimental, 2001, 50, 86-92.	1.5	97
241	Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism: Clinical and Experimental, 2001, 50, 425-435.	1.5	496
242	Constitutive activation of STAT-3 and downregulation of SOCS-3 expression induced by adrenalectomy. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R2048-R2058.	0.9	31
243	Evaluation of body fat in fatter and leaner 10-y-old African American and white children: the Baton Rouge Children's Study. American Journal of Clinical Nutrition, 2001, 73, 687-702.	2.2	127
244	Effects on blood lipids of a blood pressure–lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. American Journal of Clinical Nutrition, 2001, 74, 80-89.	2.2	500
245	Drug treatment of obesity. , 2001, 2, 403-418.		73
246	Body Composition of African American and White Children: A 2â€Year Followâ€Up of the BAROC Study. Obesity, 2001, 9, 605-621.	4.0	26
247	Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial. Annals of Internal Medicine, 2001, 135, 1019.	2.0	475
248	Differential oxidation of individual dietary fatty acids in humans. American Journal of Clinical Nutrition, 2000, 72, 905-911.	2.2	473
249	Medicinal strategies in the treatment of obesity. Nature, 2000, 404, 672-677.	13.7	388
250	A concise review on the therapeutics of obesity. Nutrition, 2000, 16, 953-960.	1.1	138
251	Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition, 2000, 16, 967-975.	1.1	92
252	Clinical Evaluation of the Overweight Patient. Endocrine, 2000, 13, 167-186.	2.2	31

#	Article	IF	CITATIONS
253	Fat and carbohydrate balances during adaptation to a high-fat diet. American Journal of Clinical Nutrition, 2000, 71, 450-457.	2.2	103
254	Concurrent physical activity increases fat oxidation during the shift to a high-fat diet. American Journal of Clinical Nutrition, 2000, 72, 131-138.	2.2	73
255	Physiological Relationships of Uncoupling Protein-2 Gene Expression in Human Adipose Tissue in Vivo1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2312-2317.	1.8	26
256	Afferent signals regulating food intake. Proceedings of the Nutrition Society, 2000, 59, 373-384.	0.4	201
257	Current and Potential Drugs for Treatment of Obesity. Endocrine Reviews, 1999, 20, 805-875.	8.9	263
258	The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-Sodium). Journal of the American Dietetic Association, 1999, 99, S96-S104.	1.3	164
259	Differential Satiating Effects of Fats in the Small Intestine of Obesity-Resistant and Obesity-Prone Rats. Physiology and Behavior, 1999, 66, 621-626.	1.0	39
260	Testosterone Administration Preserves Protein Balance But Not Muscle Strength during 28 Days of Bed Rest1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 207-212.	1.8	31
261	Serial Echocardiographic and Clinical Evaluation of Valvular Regurgitation Before, During, and After Treatment with Fenfluramine or Dexfenfluramine and Mazindol or Phentermine. Obesity, 1999, 7, 313-322.	4.0	68
262	Sibutramine Produces Doseâ€Related Weight Loss. Obesity, 1999, 7, 189-198.	4.0	333
263	Pharmaceutical Cost Savings of Treating Obesity with Weight Loss Medications. Obesity, 1999, 7, 523-531.	4.0	58
264	Dietary Fat Preferences Are Inversely Correlated with Peripheral Gustatory Fatty Acid Sensitivitya. Annals of the New York Academy of Sciences, 1998, 855, 165-168.	1.8	118
265	Obesity: a time bomb to be defused. Lancet, The, 1998, 352, 160-161.	6.3	144
266	%β3adrenergicagonist%Satiety. Physiology and Behavior, 1998, 63, 723-728.	1.0	48
267	In Defense of a Body Mass Index of 25 as the Cutâ€off Point for Defining Overweight. Obesity, 1998, 6, 460-462.	4.0	17
268	The Effects of a High Fat Diet on Leptin mRNA, Serum Leptin and the Response to Leptin Are Not Altered in a Rat Strain Susceptible to High Fat Diet-Induced Obesity. Journal of Nutrition, 1998, 128, 1606-1613.	1.3	62
269	Feeding Response to Mercaptoacetate in Osborneâ€Mendel and S5B/PL Rats. Obesity, 1997, 5, 587-594.	4.0	23
270	The Thermic Effect of Food and Obesity: A Critical Review. Obesity, 1997, 5, 622-631.	4.0	133

#	Article	IF	CITATIONS
271	Archeology of Mindâ€"Obesity and Psychoanalysis. Obesity, 1997, 5, 153-156.	4.0	1
272	A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. New England Journal of Medicine, 1997, 336, 1117-1124.	13.9	4,957
273	Eat Slowly — From Laboratory to Clinic; Behavioral Control of Eating. Obesity, 1996, 4, 397-400.	4.0	3
274	Static Theories in a Dynamic World: A Glucodynamic Theory of Food Intake. Obesity, 1996, 4, 489-492.	4.0	19
275	Methods and Obesity Research: The Radioimmunoassay of Insulin. Obesity, 1996, 4, 579-582.	4.0	1
276	Hereditary Adiposity in Mice: Human Lessons From the Yellow and Obese (OB/OB) Mice. Obesity, 1996, 4, 91-95.	4.0	5
277	Comparison of Osborneâ€Mendel and S5B/PL Strains of Rat: Central Effects of Galanin, NPY, βâ€Casomorphin and CRH on Intake of Highâ€Fat and Lowâ€Fat Diets. Obesity, 1996, 4, 117-124.	4.0	49
278	Body Fat Distribution and the Distribution of Scientific Knowledge. Obesity, 1996, 4, 189-192.	4.0	4
279	A Doubleâ€Blind Randomized Placebo ontrolled Trial of Sibutramine. Obesity, 1996, 4, 263-270.	4.0	173
280	Obesity and Surgery for a Chronic Disease. Obesity, 1996, 4, 301-303.	4.0	2
281	Leptin and leptinomania. Lancet, The, 1996, 348, 140-141.	6.3	59
282	Energy Expenditure in Lean and Obese Prepubertal Children. Obesity, 1995, 3, 67-72.	4.0	66
283	Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). Annals of Epidemiology, 1995, 5, 108-118.	0.9	392
284	Obesity Research and Medical Journalism. Obesity, 1995, 3, 65-71.	4.0	8
285	The Association of Body Weight, Dietary Intake, and Energy Expenditure with Dietary Restraint and Disinhibition. Obesity, 1995, 3, 153-161.	4.0	152
286	From Very‣owâ€Energy Diets to Fasting and Back. Obesity, 1995, 3, 207-209.	4.0	0
287	The Indexing Waltz. Obesity, 1995, 3, 357-359.	4.0	0
288	Laurence, Moon, Bardet, and Biedl: Reflections on a Syndrome. Obesity, 1995, 3, 383-386.	4.0	11

#	Article	IF	CITATIONS
289	Luxuskonsumption ―Myth or Reality?. Obesity, 1995, 3, 491-495.	4.0	9
290	The Tide Shifts Again: The Ebb and Flow of History. Obesity, 1995, 3, 605-608.	4.0	2
291	Evaluation of Drugs for Treating Obesity. Obesity, 1995, 3, 425S-434S.	4.0	45
292	Topical Fat Reduction. Obesity, 1995, 3, 561S-568S.	4.0	41
293	Nutrient Intake is Modulated By Peripheral Peptide Administration. Obesity, 1995, 3, 569S-572S.	4.0	28
294	Vagalâ€Central Nervous System Interactions Modulate the Feeding Response to Peripheral Enterostatin. Obesity, 1994, 2, 527-534.	4.0	37
295	Extracellular Hypothalamic Monoamines Measured by In Vivo Microdialysis in a Rat Model of Dietary Fatâ€Induced Obesity. Obesity, 1994, 2, 100-109.	4.0	13
296	d-Fenfluramine in a rat model of dietary fat-induced obesity. Pharmacology Biochemistry and Behavior, 1993, 45, 487-493.	1.3	26
297	The Nutrient Balance Hypothesis: Peptides, Sympathetic Activity, and Food Intake. Annals of the New York Academy of Sciences, 1993, 676, 223-241.	1.8	52
298	Use and Abuse of Appetite-Suppressant Drugs in the Treatment of Obesity. Annals of Internal Medicine, 1993, 119, 707.	2.0	159
299	Pancreatic procolipase propeptide, enterostatin, specifically inhibits fat intake. Physiology and Behavior, 1991, 49, 1191-1194.	1.0	102
300	Reciprocal relation between the sympathetic nervous system and food intake. Brain Research Bulletin, 1991, 27, 517-520.	1.4	73
301	Enterostatin suppresses food intake following injection into the third ventricle of rats. Brain Research, 1991, 544, 137-140.	1.1	81
302	Obesity, A Disorder Of Nutrient Partitioning: The MONA LISA Hypothesis. Journal of Nutrition, 1991, 121, 1146-1162.	1.3	212
303	Brain 3-hydroxybutyrate, glutamate, and GABA in a rat model of dietary obesity. Physiology and Behavior, 1989, 45, 571-577.	1.0	32
304	Drug Treatment of Obesity. Medical Clinics of North America, 1989, 73, 237-249.	1.1	35
305	Brain uptake of ketones in rats with differing susceptibility to dietary obesity. Metabolism: Clinical and Experimental, 1987, 36, 27-30.	1.5	31
306	The energetics of obesity. Medicine and Science in Sports and Exercise, 1983, 15, 32???40.	0.2	23

#	Article	IF	CITATIONS
307	Hepatic Sodium-Potassium-Dependent ATPase in Obesity. New England Journal of Medicine, 1981, 304, 1580-1582.	13.9	60
308	Ventromedial hypothalamus modulates fat mobilisation during fasting. Nature, 1978, 274, 900-902.	13.7	131
309	Effect of transplantation of pancreas on development of hypothalamic obesity. Nature, 1977, 266, 742-744.	13.7	71
310	MANIFESTATIONS OF HYPOTHALAMIC OBESITY IN MAN: A COMPREHENSIVE INVESTIGATION OF EIGHT PATIENTS AND A EEVIEW OF THE LITERATURE. Medicine (United States), 1975, 54, 301-330.	0.4	211
311	The acute effects of food intake on energy expenditure during cycle ergometry. American Journal of Clinical Nutrition, 1974, 27, 254-259.	2.2	80
312	Fogarty Center Conference on Obesity. American Journal of Clinical Nutrition, 1974, 27, 423-424.	2.2	2
313	Reproductive Function in the Genetically Obese "Fatty―Rat. Endocrinology, 1973, 93, 1251-1256.	1.4	69
314	Effect of triiodothyronine on some metabolic responses of obese patients. American Journal of Clinical Nutrition, 1973, 26, 715-721.	2.2	41
315	Exercise energetics in normal man following acute weight gain. American Journal of Clinical Nutrition, 1973, 26, 1284-1286.	2.2	25
316	Effect of triiodothyronine on some metabolic responses of obese patients. American Journal of Clinical Nutrition, 1973, 26, 715-721.	2.2	36
317	Lipogenesis in Human Adipose Tissue: Some Effects of Nibbling and Gorging. Journal of Clinical Investigation, 1972, 51, 537-548.	3.9	94
318	Reply to Dr. Schauf. American Journal of Clinical Nutrition, 1971, 24, 288-289.	2.2	0
319	A simple efficient liquid scintillator for counting aqueous solutions in a liquid scintillation counter. Analytical Biochemistry, 1960, 1, 279-285.	1.1	7,552
320	Hemopericardium with Cardiac Tamponade in Chronic Uremia. New England Journal of Medicine, 1957, 257, 230-231.	13.9	39